Recommended

Discover how to overcome low affinity or poor TCR yields that are slowing you down in this upcoming webinar – register your details today
Facing roadblocks in obesity drug discovery? Discover how integrated, validated strategies are helping teams accelerate development and reduce risk – register your details now
Unlock the science, strategy and real-world impact behind the next generation of precision therapies – access our new brand report now >>
Safety data is no longer just a regulatory checkbox – it’s a strategic advantage. Find out more in our upcoming webinar, register your details today
Explore how AI is reshaping early drug discovery, from target identification and compound screening to predictive modelling and trial design – register now!
news

New leukaemia treatment outperforms standard chemotherapies

Researchers at The Australian National University (ANU) are working on a new treatment for an aggressive type of leukaemia that outperforms standard chemotherapies.

treatment

Researchers at The Australian National University (ANU) are working on a new treatment for an aggressive type of leukaemia that outperforms standard chemotherapies.

Lead researcher Dr Nadine Hein from The John Curtin School of Medical Research at ANU said researchers have successfully treated highly aggressive acute myeloid leukemia (AML) in mice using the new treatment.

“Not only have we been able to reduce the number of cancer cells, we have been able to reduce the number of cancer stem cells that tend to develop or be resistant to chemotherapy and are thought to be responsible for disease relapse in patients,” Dr Hein said.

Targeting protein

Dr Hein said researchers used a compound known as CX-5461 to target the protein-making process within the cancer cells.

 

Reserve your FREE place

 


Reduce preclinical failures with smarter off-target profiling

24 September 2025 | 15:00PM BST | FREE Webinar

Join this webinar to hear from Dr Emilie Desfosses as she shares insights into how in vitro and in silico methods can support more informed, human-relevant safety decisions -especially as ethical and regulatory changes continue to reshape preclinical research.

What you’ll learn:

  • Approaches for prioritizing follow-up studies and refining risk mitigation strategies
  • How to interpret hit profiles from binding and functional assays
  • Strategies for identifying organ systems at risk based on target activity modulation
  • How to use visualization tools to assess safety margins and compare compound profiles

Register Now – It’s Free!

 

“We are working towards a treatment that will improve on the current chemotherapy options and improve the patient’s prognosis,” Dr Hein said

Around 1,000 people are diagnosed with AML in Australia each year and, depending on the patient’s age, there is a high rate of mortality with only about 30 percent surviving long term.

Canberra haematologist and ANU Senior Lecturer Dr James D’Rozario said the standard approach to treating AML hasn’t changed in over 30 years.

“Novel agents such as CX-5461 with more sophisticated mechanisms of action are desperately required to improve outcomes in patients with this group of illnesses,” Dr D’Rozario said.

Professor Ross Hannan, Head of the ACRF Department of Cancer Biology and Therapeutics at JCSMR, said that based on the promising preclinical results, a Phase 1 clinical trial for the treatment of patients with blood cancer has just been completed in Australia. Results are expected to be published later this year.

“Another Phase 1/ Phase 2 clinical trial is underway in Canada for the treatment of patients with solid tumours,” Professor Hannan said.

Leave a Reply

Your email address will not be published. Required fields are marked *